Citi raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $16 from $12 and keeps a Buy rating on the shares following the Q3 report. The firm views the early data for ORIC-944 as promising.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications
- Promising Potential of ORIC-944 in mCRPC Treatment Boosts Buy Rating and Price Target
- Oric Pharmaceuticals price target raised to $23 from $19 at H.C. Wainwright
- Promising Developments and Strong Cash Position Justify Buy Rating for ORIC Pharmaceuticals
- Oric Pharmaceuticals price target raised to $15 from $12 at Oppenheimer